Cyberknife Radioablation of Prostate Cancer – Preliminary Results for 400 Patients

Miszczyk, Leszek; Namysł-Kaletka, Agnieszka; Napieralska, Aleksandra; Wozniak, Grzegorz; Stapor-Fudzinska, Małgorzata; Glowacki, Grzegorz; Tukiendorf, Andrzej

doi:10.22034/APJCP.2017.18.4.1007

Cyberknife Radioablation of Prostate Cancer – Preliminary Results for 400 Patients

Document Type : Research Articles

Authors

¹ Radiotherapy Department,M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland.

² Treatment Planning, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland.

³ Department of Epidemiology,M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland.

10.22034/APJCP.2017.18.4.1007

Abstract

Objectives: To evaluate the tolerance and effectiveness of stereotactic ablative radiotherapy (SABR) applied in the treatment of low and intermediate risk (LR & IR) prostate cancer patients (PCP) and provide an evaluation of the level of risk group impact on treatment results. In addition, androgen deprivation therapy (ADT) usage and prostatic specific antigen (PSA) decline after SABR were assessed. Material and Methods: A total of 400 PCP (213 LR and 187 IR, including T2c) were irradiated with a CyberKnife using fd 7.25 Gy to TD 36.25 Gy. At the start of treatment, 60.3% of patients were undergoing ADT and this gradually decreased to 0% after 38 months. Follow-up was for a median of 15.0 months. Patients were monitored on SABR completion and 1, 4, 8 months later and then subsequently every 6 months. GI (Gastro-Intestinal) and GU (Genito-Urinary) acute and late adverse effects, PSA and ADT usage were evaluated. Results: Failure was noted in 9 patients (2.25%) (5 in LR and 4 in IR groups) - 4 relapses and 5 nodal metastases. No G3/4 late adverse effects (EORTC/RTOG) were observed. Some 0.5% of G3 GU and 0.3% of G3 GI acute reactions were noted respectively on the SABR completion day and one month later. The median of PSA declined 1.5 ng/ml during the first month and 0.6 ng/ml during the next three months. No impact of risk groups on treatment results was found. An impact of ADT on PSA decline was only confirmed for time point interactions. Conclusions: SABR for LR and IR PCP is a safe and effective treatment. The inclusion of T2c patients and the low percentage of IR patient failure permit us the assumption that this procedure could be utilized in the treatment of more advanced cases. The results do not allow clear definition of the impact of ADT on radioablation results in LR and IR+ T2c cases.

Keywords